▎ 摘　　要

NOVELTY - Detecting methimazole (MTZ) in a sample, comprises contacting the sample containing MTZ with a substrate comprising graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag) to adsorb the MTZ onto the G-D-Ag, and performing surface-enhanced raman scattering (SERS) by exposing the substrate with the G-D-Ag adsorbed MTZ to a focused laser beam and recording vibrational frequencies, determining the presence of MTZ by the vibrational frequencies emitted by the SERS, where the G-D-Ag comprise a graphene oxide sheet chemically bonded with at least 2 polyamidoamine (PAMAM) dendrimers through carboxamide bonds (I), and silver nanoparticles bound to the graphene oxide sheet supported polyamidoamine (PAMAM) dendrimer, where a weight ratio of the silver nanoparticles relative to the graphene oxide sheet is 1:1-3:1. USE - The method is useful for: detecting methimazole (MTZ) in a sample e.g. pharmaceutical, drug or chemical sample and not a biological sample from a subject, sample obtained from domestic cat or other member of the family Felidae, sample from a subject having hyperthyroidism or at risk, sample from a female who is pregnant or who may become pregnant, sample from a subject having, genetically predisposed to having, or at risk of having agranulocytosis, aplastic anemia (pancytopenia), ANCA-positive vasculitis, exfoliative dermatitis, hepatitis, or hepatic dysfunction or at least one symptom, or sample from a subject having anorexia, pruritus, or right upper quadrant pain or other symptom of hepatic dysfunction or sample from a subject having abnormal liver function test (all claimed). ADVANTAGE - The method exhibits use in low-detection limit drug analysis, is rapid and accurate.